Generali Investments Management Co LLC Purchases 26,237 Shares of Stoke Therapeutics, Inc. $STOK

Generali Investments Management Co LLC raised its position in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 379.6% during the second quarter, Holdings Channel.com reports. The institutional investor owned 33,149 shares of the company’s stock after purchasing an additional 26,237 shares during the quarter. Generali Investments Management Co LLC’s holdings in Stoke Therapeutics were worth $1,085,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Hussman Strategic Advisors Inc. acquired a new position in shares of Stoke Therapeutics in the 4th quarter worth approximately $2,000,000. Baillie Gifford & Co. bought a new stake in Stoke Therapeutics during the 4th quarter worth approximately $7,837,000. Dimensional Fund Advisors LP increased its holdings in Stoke Therapeutics by 19.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 989,936 shares of the company’s stock valued at $32,229,000 after purchasing an additional 162,797 shares in the last quarter. Candriam S.C.A. increased its holdings in Stoke Therapeutics by 12.4% during the 1st quarter. Candriam S.C.A. now owns 502,020 shares of the company’s stock valued at $16,346,000 after purchasing an additional 55,330 shares in the last quarter. Finally, Janus Henderson Group PLC raised its position in Stoke Therapeutics by 11.2% in the 1st quarter. Janus Henderson Group PLC now owns 1,612,781 shares of the company’s stock valued at $52,456,000 after purchasing an additional 161,848 shares during the last quarter.

Insider Activity

In other news, General Counsel Jonathan Allan sold 1,457 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $29.95, for a total value of $43,637.15. Following the transaction, the general counsel owned 18,086 shares of the company’s stock, valued at approximately $541,675.70. This trade represents a 7.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Barry Ticho sold 7,176 shares of Stoke Therapeutics stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $29.04, for a total transaction of $208,391.04. Following the sale, the insider owned 20,422 shares of the company’s stock, valued at approximately $593,054.88. This represents a 26.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 10,428 shares of company stock valued at $306,919 over the last three months. Company insiders own 9.60% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on STOK shares. Guggenheim reissued a “buy” rating and issued a $60.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, August 4th. Weiss Ratings restated a “sell (d)” rating on shares of Stoke Therapeutics in a research note on Friday. The Goldman Sachs Group initiated coverage on Stoke Therapeutics in a report on Monday, July 13th. They issued a “buy” rating and a $44.00 price target for the company. Canaccord Genuity Group reduced their price target on shares of Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating on the stock in a research report on Tuesday, August 4th. Finally, Chardan Capital reissued a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, August 4th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.00.

Stoke Therapeutics Stock Performance

NASDAQ STOK opened at $32.23 on Tuesday. The stock has a fifty day moving average of $30.49 and a 200-day moving average of $32.10. The stock has a market capitalization of $2.08 billion, a P/E ratio of -9.65 and a beta of 1.20. Stoke Therapeutics, Inc. has a 52 week low of $12.86 and a 52 week high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.13). Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. The firm had revenue of $9.32 million for the quarter, compared to analyst estimates of $4.89 million. Equities research analysts forecast that Stoke Therapeutics, Inc. will post -3.5 earnings per share for the current fiscal year.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.